Published in final edited form as:

Tetrahedron Lett. 2016 October 19; 57(42): 4749–4753. doi:10.1016/j.tetlet.2016.09.040.

Replacement of the Bryostatin A- and B-Pyran Rings With Phenyl Rings Leads to Loss of High Affinity Binding With PKC

Mark E. Petersen[†], Noemi Kedei[‡], Nancy E. Lewin[‡], Peter M. Blumberg[‡], and Gary E. Keck^{†,*}

[†]University of Utah, Department of Chemistry, Salt Lake City, UT, 84112, USA

[‡]Laboratory of Cancer Biology and Genetics, NCI, National Institutes of Health, Bethesda, MD 20892-4255, USA

Abstract

We describe a convergent synthesis of a bryostatin analogue in which the natural A- and B-ring pyrans have been replaced by phenyl rings. The new analogue exhibited PMA like behavior in cell assays, but failed to maintain high affinity binding for PKC, despite retaining an unaltered C-ring ‘binding domain’

Graphical Abstract

Keywords

Bryostatin; analogues; PKC; SAR; Cross coupling; Heck reaction

Introduction

Bryostatin 1 is a marine macrolide that was isolated from *Bugula neritina* in 1982 by Petit and co-workers.¹ In total, 20 naturally occurring bryostatins have been isolated. Bryostatin 1 has been the subject of more than 80 phase 1 and phase 2 clinical trials for the treatment of various cancers,² as well as recent phase 1 and 2 trials for the treatment of Alzheimer's disease.^{3,4} Additional clinical indications include effects on learning and memory,⁵ and

* Keck@chem.utah.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

activation of latent HIV reservoirs.⁶ Bryostatin 1 elicits biological responses primarily through binding the C1 domain of protein kinase C (PKC). However, activation of PKC through binding the C1 domain with an exogenous ligand has been shown to elicit diverse and often contrasting biological responses. Binding of another high affinity ligand, phorbol 12-myristate 13-acetate (PMA) leads to potent tumor promotion in mouse skin⁷ whereas prostratin, another phorbol ester, and bryostatin 1 are not tumor-promoting. Bryostatin 1 is unique among C1 domain ligands in that it is capable of antagonizing the biological function of other C1 domain ligands. For instance, PMA induces attachment and inhibits proliferation of U937 leukemia cells; if co-administered with PMA, bryostatin 1 blocks these effects in a dose dependent manner.⁸

Currently, one of the major obstacles to further clinical development of bryostatin 1 is its extremely low natural abundance. Harvesting from natural sources is low yielding and environmentally devastating, culturing *Bugula neritina* or the bryostatin producing symbiotic bacterium *Candidatus endobugula* have yet to be successfully realized, and chemical synthesis requires many steps. Thus, structurally simplified analogues have attracted considerable attention as potential bryostatin substitutes.^{9,10}

Structurally, bryostatin 1 is comprised of 3 highly functionalized pyran rings (A, B, and C) contained within a 20-membered macrolactone (Figure 1). Early studies with synthetic and semi-synthetic analogues suggested that binding with PKC is mediated primarily by substituents on the C-ring. Modification/elimination of the C19 hemiketal or C26 hydroxyl leads to substantial loss in binding affinity.¹¹ Conversely, modification or omission of A- and/or B-ring substituents has a minimal effect on binding. Additionally, a macrocyclic structure is required, leading to a hypothesis that the A- and B-ring pyrans act as a 'spacer domain,' orienting the C-ring substituents in their optimal binding orientation.^{12,13,14} This initial hypothesis is reasonably accurate with regard to maintaining PKC binding affinity; however, ligand binding is just the first event of a complex biological response mediated by PKC activation. Through a series of detailed studies in which contributions of the A- and B-ring substituents were evaluated, it was shown that this region is not merely a spacer domain but rather imparts to bryostatin its unique biological profile. Analogues **Merle 28**¹⁵ and **Merle 30**,¹⁶ which contain two oxygen 'polar' functionalities on the A- and B-rings, were found to be bryo-like in U937 cells while **Merle 23**⁸ and **Merle 32**,¹⁷ which contain no polar functionalities, were found to be PMA-like. Reintroducing just the C7 acetate on the bis-pyran scaffold (**Merle 27**, not shown) provided an analogue that retained PMA-like behavior, suggesting that a single polar group is not sufficient to confer bryo-like behavior.¹⁸ In addition to investigating the role of the A-, and B-ring substituents both individually and in combination, we have also sought to simplify the synthesis of analogues through omission of non-essential moieties. A recent example is the synthesis of **Merle 42**,¹⁹ which contains 2 polar groups on the A-ring, consistent with **Merle 28**, but has the B-ring deleted in favor of a simple ester linkage. Interestingly, this analogue demonstrated PMA-like behavior suggesting that the B-ring, regardless of polar substituents on the A-ring, plays an important role in maintaining a bryostatin-like response. Similar biological results were also observed with another B-ring truncated analogue, WN-1.²⁰ Herein, through the synthesis of bis-phenyl analogue **Merle 40**, we report an attempt to develop a new scaffold that encompasses

both an A- and a B-ring. This scaffold was designed to be highly modular in that the A-ring, B-ring, or both could be replaced with differentially functionalized phenyl rings, allowing us to further investigate the effect of polar substituents in this region of the molecule.

Results and discussion

Synthesis of Merle 40

Retrosynthetically, we envisioned accessing **Merle 40** through the union of a bis-phenyl A, B-ring segment with a fully functionalized C-ring subunit. Specifically, we sought to use a Heck insertion to combine a B-ring aryl bromide with a C-ring olefin, followed by oxidation of the C1 alcohol, macrolactonization, and global deprotection. For the C-ring portion of the molecule an acetate ester at C20, as opposed to the natural bryostatin 1 (2E,4E)-octa-2,4-dienoate ester, was chosen. The C20 ester is synthetically more convenient, and through the synthesis of bryostatin 7 ($K_i = 0.26$ nM)²² and a C20 acetate version of Merle 23 ($K_i = 0.6$ nM)²³ we have shown that this substitution has a minimal effect on PKC binding.

Our first concern for executing this strategy was developing an efficient synthesis of the bis-phenyl A, B-ring subunit. Our route began (Scheme 1) with the coupling of 3-bromobenzyl bromide **1** (B-ring) with the Molander salt **2** derived from 3-bromobenzaldehyde (A-ring).²⁴ Following homoelongation of aldehyde **3**, using Levine's two-step protocol²⁵ the sole stereocenter was set using a catalytic asymmetric allylation.²⁶ The free alcohol at C3 was protected as a TES ether, and the terminal olefin was converted to a primary alcohol in a two-step, single flask, ozonolysis/reduction sequence. The bis-phenyl A, B-ring subunit **6** contains only one stereocenter, compared to six in bryostatin 1, or five in our most studied analogue **Merle 23**. As a result **6** could be synthesized in only 7 chemical manipulations.

Our initial strategy for completing **Merle 40** was to advance glycal **7**²⁷ with the C26 alcohol protected as a benzyloxymethyl (BOM) ether (Scheme 2). This strategy eventually failed because suitable conditions for removal of the BOM group, as the final step, without decomposition of the analogue, could not be found. The ultimately successful route required that the BOM ether be removed first. This was accomplished using a dissolving metal reduction, which allowed the BOM group to be cleanly removed while leaving the more electron rich PMB ether at C25 intact. The free C26 alcohol was then re-protected as a TBS ether. The first step in oxidizing glycal **8** to the fully functionalized C-ring was epoxidation of the enol-ether with MMPP. *In-situ* addition of methanol to the axial position opened the epoxide to give a ~4:1 mixture of C19 hemiketal diastereomers. The hemiketal was then equilibrated to a single C19 diastereomer with chloroacetic acid, and the C20 alcohol oxidized to a ketone.²⁸ At this point the desired C-ring was completed utilizing steps that were previously optimized during our synthesis of bryostatin 1.²⁹ First, the exocyclic enoate was installed using a one-pot aldol addition/elimination reaction and finally the C20 ketone was reduced and the resulting alcohol esterified with acetic anhydride to give C-ring **11**.

At the outset we were aware that the prenyl olefin of **11** was likely to exhibit very low reactivity. Evans and coworkers encountered challenges using a C17 aldehyde of a fully functionalized C-ring in a Julia olefination during their bryostatin 2 synthesis,²⁸ and Trost was unable to use a C16–17 prenyl olefin of a similarly functionalized C-ring in metathesis

reactions.³⁰ A Heck reaction on this substrate is particularly challenging, requiring an intermediate in which the bulky palladium-ligand complex must occupy a position vicinal to the C18 gem-dimethyl. Initial attempts using conditions developed by Jeffery (Pd(OAc)₂, K₂CO₃, n-Bu₄N⁺Cl⁻)³¹ or a specialized Buchwald ligand (SPHOS)²⁷ afforded oxidative addition of the B-ring aryl bromide, but without olefin insertion. Attempts to push the reaction through the use of alkoxide or carbonate bases or using elevated temperatures caused decomposition of the C-ring component. After considerable catalyst screening, a set of conditions developed by the Fu group (Pd₂(dba)₃/P(tBu)₃/Cy₂NMe) provided a solution.³³ Combining Pd(P(tBu)₃)₂ and Pd₂(dba)₃, both air stable, in a 2:1 ratio followed by thorough degassing allowed this reaction to be conducted without the use of a glove box, and under these conditions the reaction proceeded to 50% completion. Also, use of Cy₂NMe as the base in the reaction proved to be essential, with no product observed when other tertiary amines were utilized. This result is consistent with Fu's observations about the unusual reactivity of Cy₂NMe in palladium catalyzed cross coupling reactions.³³

After successfully uniting the two fragments, the primary alcohol at C1 was oxidized over two steps to give carboxylic acid **13**.³⁴ Next, the C25 PMB ether was removed with DDQ, and the macrolactone was closed using Yamaguchi conditions. Unfortunately, attempts to remove all three protecting groups on compound **14** in a single step resulted in a mixture of products. In addition to the desired analogue, two additional compounds were observed. One, easily separable, was the result of elimination of the C19 hemiketal to give a cyclic enol ether. The second compound appeared to be the result of a 1,2-acyl shift of the C25 ester to the C26 alcohol, giving a ring-expanded 21-membered macrolactone. A similar ring expanded compound was also observed in the synthesis of **Merle 42**, in which the B-ring pyran was replaced by an ester linkage.¹⁹ In the case of **Merle 42**, the ring expanded compound, **Merle 43**, was separable, however; even under very mild conditions, the desired 20-membered macrolactone underwent a facile and energetically favorable rearrangement to the 21-membered macrolactone. Interestingly, both **Merle 42** and **Merle 43** bound PKC with nanomolar affinity (K_i = 0.75 nM, and 13.8 nM). Given that oxidation of the C26 hydroxyl to a ketone³⁵ or protecting it as an acetate ester¹³ block nanomolar PKC binding, this result suggests that the free alcohol at C25 is able to partially fulfill the role of the C26 alcohol in binding PKC. In the case of **Merle 40** we were unable to separate the two isomers; however, quenching the reaction prior to complete removal of the C26 TBS minimized formation of the ring-expanded compound. Unfortunately, further treatment of **15** with HF•Pyr, TBAF, TSAF, or various Lewis acids all resulted in mixtures of ring expansion, elimination and/or decomposition.

Biological evaluation of Merle 40

In spite of troubles removing the final protecting groups, we did obtain a sufficient quantity of **Merle 40** with reasonable purity for an initial biological comparison with bryostatin 1 and PMA. **Merle 40** demonstrated a K_i = ~ 1 μ M for PKC α compared to a K_i = 0.48 nM for bryostatin 1 and a K_i = 0.70 nM for our most studied analogue **Merle 23**. In the U937 cell attachment and proliferation assay PMA inhibits growth and induces attachment while bryostatin 1 has little effect on either. Bryostatin 1, however, is able to block the effects of PMA in a dose dependent manner. In this assay **Merle 40** behaves similarly to PMA in that

it induces both attachment and proliferation and does not block the effects of PMA when co-administered (Figure 2). This result was expected and is consistent with the behavior of **Merle 23** and **Merle 32**, which also lack any polar functionality on the A, B-ring portion of the molecule. Also, the loss of potency in this assay is consistent with the ~1,000 fold loss in binding affinity. Loss of potency is even more evident in Toledo cells where both PMA and bryostatin 1 inhibit growth with subnanomolar potency, and **Merle 40** requires micromolar concentrations to achieve comparable inhibition (Figure 3).

In summary, we have prepared a bryostatin analogue, **Merle 40**, where both the A- and B-ring pyrans were replaced by simple aromatic building blocks. **Merle 40** was found to be unstable and to have a propensity for elimination of the C19 hemiketal as well as for ring expansion to form a 21-membered macrolactone. However, unlike our previously reported compounds, **Merle 42 and 43**, that had propensity for ring expansion, the bis-phenyl analogue **Merle 40** did not retain high affinity PKC binding. It seems likely that this is due to the complete loss of the internal H-bonding network which is observed in bryostatin 1 and in analogues which retain the bis-pyran A, B-rings, the C-19 hemiketal, and the C3 hydroxyl substituent. Loss of this hydrogen-bonding network is also likely to be responsible for the lack of stability under conditions previously used to remove a C26 TBS protecting group during Wender's bryostatin 9 synthesis.³⁶ In agreement with our previous observations that the presence of polar functionality displayed on A- and B-ring pyrans promotes bryo-like behavior, the activity of **Merle 40** in U937 cells was similar to PMA and to analogues **Merle 23** and **Merle 32**.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Financial support was provided by the NIH through Grant GM28961 and through the Intramural Research Program, CCR, NCI, NIH (Project Z1A BC 005270).

References

1. Pettit GR, Herald CL, Doubek DL, Herald DL. J Am Chem Soc. 1982; 104:6846.
2. Newman DJ, Cragg GM. J Nat Prod. 2004; 67:1216. [PubMed: 15332835]
3. Etcheberrigaray R, Tan M, Dewachter I, Kuiperi C, Van der Auwera I, Wera S, Qiao L, Bank B, Nelson TJ, Kozikowski AP, Van Leuven F, Alkon DL. Proc Natl Acad Sci U S A. 2004; 101:11141. [PubMed: 15263077]
4. Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M. The Lancet Neurology. 2010; 9:702. [PubMed: 20610346]
5. Alkon DL, Epstein H, Kuzirian A, Bennett MC, Nelson TJ. Proc Natl Acad Sci U S A. 2005; 102:16432. [PubMed: 16258064]
6. Sanchez-Duffhues G, Vo MQ, Perez M, Calzado MA, Moreno S, Appendino G, Munoz E. Current Drug Targets. 2011; 12:348. [PubMed: 20955147]
7. Hecker E. Cancer Research. 1968; 28:2338. [PubMed: 5723975]
8. Keck GE, Kraft MB, Truong AP, Li W, Sanchez CC, Keddi N, Lewin NE, Blumberg PM. J Am Chem Soc. 2008; 130:6660. [PubMed: 18452293]
9. Wender PA, Loy BA, Schrier AJ. Isr J Chem. 2011; 51:453. [PubMed: 22661768]

10. Hale KJ, Manaviazar S. *J Asian Chem.* 2010; 5:704.
11. Wender PA, Cribbs CM, Koehler KF, Sharkey NA, Herald CL, Kamano Y, Pettit GR, Blumberg PM. *Proc Natl Acad Sci U S A.* 1988; 85:7197. [PubMed: 3174627]
12. Wender PA, De Brabander J, Harran PG, Jimenez JM, Koehler MFT, Lippa B, Park CM, Shiozaki M. *J Am Chem Soc.* 1998; 120:4534.
13. Wender PA, DeBrabander J, Harran PG, Jimenez J, Koehler MFT, Lippa B, Park C, Siedenbiedel C, Pettit GR. *Proc Natl Acad Sci U S A.* 1998; 95:6624. [PubMed: 9618462]
14. Wender PA, De Brabander J, Harran PG, Hinkle KW, Lippa B, Pettit GR. *Tetrahedron Lett.* 1998; 39:8625.
15. Keck GE, Poudel YB, Welch DS, Kraft MB, Truong AP, Stephens JC, Kedei N, Lewin NE, Blumberg PM. *Org Lett.* 2009; 11:593. [PubMed: 19113896]
16. Keck GE, Poudel YB, Rudra A, Stephens JC, Kedei N, Lewin NE, Peach ML, Blumberg PM. *Angew Chem Int Ed.* 2010; 49:4580.
17. Keck GE, Poudel YB, Rudra A, Stephens JC, Kedei N, Lewin NE. *Bioorg Med Chem Lett.* 2012; 22:4084. [PubMed: 22579485]
18. Keck GE, Li W, Kraft MB, Kedei N, Lewin NE, Blumberg PM. *Org Lett.* 2009; 11:2277. [PubMed: 19419164]
19. Kraft MB, Poudel YB, Kedei N, Lewin NE, Peach ML, Blumberg PM, Keck GE. *J Am Chem Soc.* 2014; 136:13202. [PubMed: 25207434]
20. Andrews IP, Ketcham JM, Blumberg PM, Kedei N, Lewin NE, Peach ML, Krische MJ. *J Am Chem Soc.* 2014; 136:13209. [PubMed: 25207655]
21. Lewin NE, Blumberg PM. *Methods Mol Biol.* 2003; 233:129. [PubMed: 12840504]
22. Kedei N, Lewin NE, Géczy T, Selezneva J, Braun DC, Chen J, Herrmann MA, Heldman MR, Lim L, Mannan P, Garfield SH, Poudel YB, Cummins TJ, Rudra A, Blumberg PM, Keck GE. *ACS Chem Biol.* 2013; 767
23. Petersen, ME. Thesis. University of Utah; Salt Lake City, UT: 2014.
24. Molander GA, Bernardi CR. *J Org Chem.* 2002; 67:8424. [PubMed: 12444620]
25. Levine SG. *J Am Chem Soc.* 1958; 80:6150.
26. Keck GE, Tarbet KH, Geraci LS. *J Am Chem Soc.* 1993; 115:8467.
27. Keck GE, Truong AP. *Org Lett.* 2005; 7:2149. [PubMed: 15901156]
28. Evans DA, Carter PH, Carreira EM, Charette AB, Prunet JA, Lautens M. *J Am Chem Soc.* 1999; 121:7540.
29. Keck GE, Poudel YB, Cummins TJ, Rudra A, Covell JA. *J Am Chem Soc.* 2010; 133:744. [PubMed: 21175177]
30. Trost BM, Yang H, Dong G. *J Eur Chem.* 2011; 17:9789.
31. Jeffery T. *Tetrahedron.* 1996; 52:10113.
32. Martin R, Buchwald SL. *Acc Chem Res.* 2008; 41:1461. [PubMed: 18620434]
33. Littke AF, Fu GC. *J Am Chem Soc.* 2001; 123:6989. [PubMed: 11459477]
34. Bal BS Jr, WEC. *Tetrahedron.* 1981; 37:2091.
35. Wender PA, Hillinski MK, Mayweg AVW. *Org Lett.* 2005; 7:79. [PubMed: 15624982]
36. Wender PA, Schrier AJ. *J Am Chem Soc.* 2011; 133:9228. [PubMed: 21618969]

Highlights

- Step efficient chemical synthesis of a novel bryostatin analogue.
- Use of Heck reaction between an aryl bromide and a prenyl olefin to unite late stage intermediates.
- Dramatic loss of stability and binding suggests that an internal H-bonding network is critical for both.

Figure 1.

Bryostatin 1, phorbol esters, and selected analogues: K_i values were determined by inhibition of binding of ^3H -labeled PDBu to PKC α .²¹ 'PMA- or Bryo-like' refers to behavior on U937 cell proliferation and attachment.

Figure 2.
U937 growth and attachment assay.

Figure 3.
Toledo cell growth assay

Scheme 1.
Synthesis of A, B-ring subunit 6

Scheme 2.
Completion of Merle 40